$-0.11 EPS Expected for Regulus Therapeutics Inc. (RGLS)

October 11, 2018 - By Winifred Garcia

Regulus Therapeutics Inc. (NASDAQ:RGLS) LogoInvestors sentiment decreased to 0.68 in Q2 2018. Its down 0.43, from 1.11 in 2018Q1. It worsened, as 7 investors sold Regulus Therapeutics Inc. shares while 12 reduced holdings. 7 funds opened positions while 6 raised stakes. 49.70 million shares or 2.00% less from 50.71 million shares in 2018Q1 were reported.
Bnp Paribas Arbitrage Sa holds 0% of its portfolio in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 4 shares. State Street Corp accumulated 26,075 shares or 0% of the stock. Brookstone Capital Mngmt reported 13,200 shares or 0% of all its holdings. Nea Mgmt has invested 0.34% of its portfolio in Regulus Therapeutics Inc. (NASDAQ:RGLS). Blackrock holds 0% or 585,357 shares. Rhenman Prns Asset Mgmt owns 492,878 shares. Moreover, Meeder Asset Mngmt has 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 7,434 shares. Dowling And Yahnke Ltd Liability reported 12,000 shares. Geode Ltd invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Northern Tru reported 0% of its portfolio in Regulus Therapeutics Inc. (NASDAQ:RGLS). Renaissance Technology Ltd invested in 0% or 128,989 shares. Bvf Inc Il owns 0.88% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 13.69 million shares. The Georgia-based Invesco Limited has invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Automobile Association stated it has 22,651 shares. Panagora Asset Mngmt reported 0% of its portfolio in Regulus Therapeutics Inc. (NASDAQ:RGLS).

Analysts expect Regulus Therapeutics Inc. (NASDAQ:RGLS) to report $-0.11 EPS on November, 6.They anticipate $0.07 EPS change or 38.89 % from last quarter’s $-0.18 EPS. After having $-0.13 EPS previously, Regulus Therapeutics Inc.’s analysts see -15.38 % EPS growth. The stock decreased 3.60% or $0.08 during the last trading session, reaching $2.14. About 88,501 shares traded. Regulus Therapeutics Inc. (NASDAQ:RGLS) has declined 82.14% since October 11, 2017 and is downtrending. It has underperformed by 97.76% the S&P500.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

Among 3 analysts covering Regulus (NASDAQ:RGLS), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Regulus had 4 analyst reports since May 17, 2018 according to SRatingsIntel. As per Friday, July 6, the company rating was maintained by FBR Capital. The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) has “Buy” rating given on Thursday, May 17 by Wedbush. Wells Fargo maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) on Friday, July 6 with “Market Perform” rating. On Tuesday, July 10 the stock rating was downgraded by Wedbush to “Neutral”.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company has market cap of $18.70 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. It currently has negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

More recent Regulus Therapeutics Inc. (NASDAQ:RGLS) news were published by: Streetinsider.com which released: “Regulus Therapeutics (RGLS) Reports 1-for-12 Reverse Share Split” on October 04, 2018. Also Seekingalpha.com published the news titled: “Regulus updates on pipeline; investors unmoved, shares down 7% after hours” on September 26, 2018. Seekingalpha.com‘s news article titled: “Regulus Therapeutics reverse splits shares 1:12” with publication date: October 04, 2018 was also an interesting one.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>